New combo therapy aims to tame recurrent head and neck cancer

NCT ID NCT04373642

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests a combination of the immunotherapy drug pembrolizumab and a short course of radiation called QUAD SHOT in 30 adults with recurrent head and neck cancer that cannot be cured. The goal is to see if the combination is safe and can shrink tumors or improve quality of life. Participants receive both treatments together, and researchers track tumor response, survival, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

pembrolizumab (a drug that helps the immune system fight cancer) plus QUAD SHOT radiotherapy (a short course of radiation)

What this could lead to

If it works, this could offer a new treatment option for people with recurrent head and neck cancer that is not curable, potentially shrinking tumors and improving quality of life.

What could go wrong

This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The combination may cause side effects like fatigue, skin reactions, or immune-related issues, and it may not work for all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States